Genetic risk models and variant classification tools are refining breast cancer risk assessment by identifying high-risk ...
The SERENA-6 trial shows a 54% reduced risk of death with camizestrant, with a median PFS of 16.6 months versus 9.2 months ...
Experts at a roundtable in Boston, Massachusetts, on November 3, 2025, discussed improving early Alzheimer disease diagnosis, addressing workforce and equity gaps, and expanding access to new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback